Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies. Its broader portfolio includes Lixiana, also known as Savaysa in some markets, an oral anticoagulant based on edoxaban.

Daiichi Sankyo was formed in 2005 through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd., two established Japanese drugmakers. The company is headquartered in Tokyo and serves markets in Japan, North America, Europe and other international regions through its global research, manufacturing and commercial operations.

Key Stats

• Today's Range: $18.09 to $18.68
• 50-Day Range: $16.00 to $18.38
• 52-Week Range: $14.98 to $27.50
• Volume: 139,481 shs
• Average Volume: 95,091 shs
• Market Capitalization: $33.70 billion
• P/E Ratio: 21.03
• Dividend Yield: 1.88%
• Price Target: N/A
• Consensus Rating: Reduce

Company Calendar

• Last Earnings: 7/31/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 17,435
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): $0.86
• Trailing P/E Ratio: 21.03
• Forward P/E Ratio: 18.65
• P/E Growth: 2.48
• Net Income: $1.72 billion
• Net Margins: 10.92%
• Pretax Margin: 12.41%
• Return on Equity: 14.35%
• Return on Assets: 6.10%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.92
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $14.10 billion
• Price / Sales: 2.39
• Cash Flow: $1.18 per share
• Price / Cash Flow: 15.31
• Book Value: $5.80 per share
• Price / Book: 3.12

Miscellaneous

• Outstanding Shares: 1,862,890,000
• Free Float: N/A
• Market Cap: $33.70 billion
• Optionable: Not Optionable
• Beta: -0.11